Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics reports developments tied to its oncology drug-development portfolio and corporate transition. The company had developed novel oncology therapies including ONCT-534, a dual-action androgen receptor inhibitor for relapsed or refractory metastatic castration-resistant prostate cancer; ONCT-808, an autologous ROR1-targeting CAR T therapy for aggressive B-cell lymphoma; and zilovertamab, an investigational ROR1 monoclonal antibody.
Recurring news themes include clinical-study updates, safety and efficacy data, financial results, termination of clinical programs, strategic-alternative activity, asset sales and the wind-down of operations.
Oncternal Therapeutics (Nasdaq: ONCT) announced a poster presentation for its Phase 3 ZILO-301 clinical trial, evaluating zilovertamab combined with ibrutinib in treating relapsed or refractory mantle cell lymphoma (R/R MCL). This trial aims to prove superior efficacy over ibrutinib alone. Interim data showcased an objective response rate (ORR) of 85% and a complete response rate (CR) of 41%, significantly higher than the historical rates of 66% and 20%, respectively. The trial initiates in Q3 2022, targeting approximately 250 patients.
Oncternal Therapeutics (Nasdaq: ONCT) has announced its participation in the Jefferies Healthcare Conference from June 8-10, 2022. The company's CEO, James Breitmeyer, will present a corporate overview on June 8th at 9:30 AM ET, and one-on-one meetings will be available.
The company focuses on developing innovative oncology therapies, with lead programs targeting ROR1 through investigational drugs like zilovertamab and ONCT-808. For more information, visit oncternal.com.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to new Head of Clinical Science, Ted Shih, on June 1, 2022. This award, part of the 2021 Employment Inducement Incentive Award Plan, includes an option to purchase 70,000 shares of common stock, vesting over four years. The approval came from Oncternal’s independent compensation committee, ensuring compliance with Nasdaq rules. Oncternal focuses on developing therapies for cancers with significant unmet medical needs, including ongoing clinical trials for its lead product, zilovertamab.
Oncternal Therapeutics announced updated interim data from the Phase 1/2 CIRLL study evaluating zilovertamab combined with ibrutinib for treating mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The overall response rate (ORR) for MCL was 85%, significantly outperforming historical data. For CLL, the ORR reached 91%, with a landmark progression-free survival (PFS) of 100% at 36 months for patients with specific prior therapies. Zilovertamab, targeting ROR1, showed a favorable safety profile, enhancing the company's confidence in moving towards a Phase 3 trial.
Oncternal Therapeutics (Nasdaq: ONCT) reported a robust business update on May 5, 2022, highlighting the upcoming initiation of the global Phase 3 study ZILO-301 for zilovertamab, targeting mantle cell lymphoma (MCL) in Q3 2022. The company plans to present interim data at ASCO 2022 for ongoing trials. A strategic partnership with Dana-Farber Cancer Institute was established to support CAR-T cell therapy ONCT-808. Moreover, ONCT-216 development was deprioritized, extending cash runway to Q3 2023 with $82.2 million in cash. The net loss for Q1 2022 was $9.9 million, or $0.20 per share.
Oncternal Therapeutics (Nasdaq: ONCT) announced the granting of an inducement award to new Clinical Data Manager, Samantha Carrington, on May 2, 2022. The award includes an option to purchase 20,000 shares of common stock, with a ten-year term and an exercise price based on the closing stock price on the grant date. The option vests over four years, with an initial 25% vesting after one year, followed by monthly installments. This award complies with Nasdaq's rules and aims to incentivize employees to join the company.
Oncternal Therapeutics (Nasdaq: ONCT) announced it will report its first quarter 2022 financial results on May 5, 2022, after market close. The management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide a comprehensive business update. Oncternal focuses on developing innovative oncology therapies targeting unmet medical needs, particularly in hematological malignancies and prostate cancer. Its clinical pipeline includes therapies such as zilovertamab and ONCT-808.
Oncternal Therapeutics (ONCT) announced the discontinuation of enrollment in the Phase 1/2 trial of ONCT-216 for Ewing sarcoma. The company is reallocating resources to focus on zilovertamab's Phase 3 study (ZILO-301), expected to start in Q3 2022, targeting mantle cell lymphoma (MCL). Oncternal also plans to submit an IND for its ROR1-targeting CAR-T therapy, ONCT-808, in mid-2022, alongside advancing the ONCT-534 program. With approximately $82.2 million in cash and no debt, the company expects to fund operations into Q3 2023.
Oncternal Therapeutics (Nasdaq: ONCT) announced the grant of an inducement award to Rachel Monet Kenny, the new Associate Director, CMC and Clinical Supply Chain, on April 1, 2022. The award includes an option to purchase 28,400 shares of common stock, vesting over four years. This move aligns with Nasdaq rules for employee incentives and aims to attract talent to support Oncternal’s focus on oncology therapies targeting unmet medical needs. The company continues to develop promising therapies like zilovertamab and ONCT-808 for various cancer treatments.
Oncternal Therapeutics announced progress in multiple clinical programs, including the Phase 3 Study ZILO-301 for treating relapsed or refractory mantle cell lymphoma (MCL) with zilovertamab and ibrutinib. Interim results exhibit an 81% objective response rate and a 35% complete response rate. The company also advanced ONCT-808 and ONCT-534 toward Investigational New Drug (IND) submissions. Financially, Oncternal reported a 2021 net loss of $31.3 million but maintains a robust cash position of $90.8 million, expected to sustain operations into mid-2023.